269 related articles for article (PubMed ID: 23439006)
1. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.
Pasero C; Olive D
Immunol Lett; 2013 Mar; 151(1-2):71-5. PubMed ID: 23439006
[TBL] [Abstract][Full Text] [Related]
2. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
4. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
5. Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review.
Karakatsanis S; Bertsias G; Roussou P; Boumpas D
Hematol Oncol; 2014 Sep; 32(3):113-9. PubMed ID: 24038528
[TBL] [Abstract][Full Text] [Related]
6. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
7. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Pasero C; Speiser DE; Derré L; Olive D
Curr Opin Pharmacol; 2012 Aug; 12(4):478-85. PubMed ID: 22445654
[TBL] [Abstract][Full Text] [Related]
8. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
9. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA.
Croft M
Trends Immunol; 2005 Jun; 26(6):292-4. PubMed ID: 15922943
[TBL] [Abstract][Full Text] [Related]
10. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting.
Pasero C; Truneh A; Olive D
Curr Mol Med; 2009 Sep; 9(7):911-27. PubMed ID: 19860669
[TBL] [Abstract][Full Text] [Related]
11. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
12. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
[TBL] [Abstract][Full Text] [Related]
14. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
[TBL] [Abstract][Full Text] [Related]
15. BTLA and HVEM cross talk regulates inhibition and costimulation.
Gavrieli M; Sedy J; Nelson CA; Murphy KM
Adv Immunol; 2006; 92():157-85. PubMed ID: 17145304
[TBL] [Abstract][Full Text] [Related]
16. Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.
Dalle S; Verronese E; N'Kodia A; Bardin C; Rodriguez C; Andrieu T; Eberhardt A; Chemin G; Hasan U; Le-Bouar M; Caramel J; Amini-Adle M; Bendriss-Vermare N; Dubois B; Caux C; Ménétrier-Caux C
Oncoimmunology; 2024; 13(1):2372118. PubMed ID: 38939518
[TBL] [Abstract][Full Text] [Related]
17. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
19. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
20. Roles of BTLA in Immunity and Immune Disorders.
Ning Z; Liu K; Xiong H
Front Immunol; 2021; 12():654960. PubMed ID: 33859648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
